PTC Therapeutics PTCT EBIT

EBIT at other companies

Sarepta Therapeutics, Inc.SRPT

$13.29M-88.5%

BioMarin PharmaceuticalsBMRN

$110.92M-59.9%

Capricor TherapeuticsCAPR

-$36.77M-47.2%

ALN

Alnylam PharmaceuticalsALNY

$231.44M+1,529%

Edgewise Therapeutics, Inc.EWTX

-$54.12M-17.7%

Dyne Therapeutics, Inc.DYN

-$125.28M-2.4%

FAQ

What is PTC Therapeutics's EBIT?

PTC Therapeutics (PTCT) reported EBIT of $44.96M in Q1 2026.

How has PTC Therapeutics's EBIT changed year-over-year?

PTC Therapeutics's EBIT decreased by 95.4% year-over-year, from $970.23M to $44.96M.

What is the long-term trend for PTC Therapeutics's EBIT?

Over 4 years (2021 to 2025), PTC Therapeutics's EBIT has grown at a 25.8% compound annual growth rate (CAGR), from -$374.45M to $938.28M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.